INT139852

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.39
First Reported 2006
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 14
Total Number 14
Disease Relevance 14.54
Pain Relevance 0.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
nodule 1
HCC (Homo sapiens)
Pain Link Frequency Relevance Heat
palliative 42 94.48 High High
agonist 13 92.52 High High
alcohol 8 89.28 High High
Pain 27 86.48 High High
Bile 4 72.92 Quite High
fibrosis 16 63.08 Quite High
Inflammation 22 50.00 Quite Low
cytokine 21 48.20 Quite Low
Pain score 7 5.00 Very Low Very Low Very Low
Analgesic 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hepatocellular Cancer 454 100.00 Very High Very High Very High
Carcinoma 284 100.00 Very High Very High Very High
Metastasis 75 99.96 Very High Very High Very High
Disease 62 99.64 Very High Very High Very High
Cancer 301 99.20 Very High Very High Very High
Recurrence 12 96.92 Very High Very High Very High
Apoptosis 338 95.28 Very High Very High Very High
Hepatotoxicity 4 94.64 High High
Cirrhosis 77 92.64 High High
Lung Cancer 9 92.04 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Major risk factors for HCC are well known and are dependent on the geographic area.
Regulation (dependent) of HCC associated with hepatocellular cancer
1) Confidence 0.39 Published 2008 Journal Semin Nucl Med Section Abstract Doc Link 18243838 Disease Relevance 1.26 Pain Relevance 0.23
More studies are required to fully understand the individual roles of the Bcl-2 proteins and how they cooperate to regulate HCC cell survival.
Regulation (regulate) of HCC associated with carcinoma
2) Confidence 0.30 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 1.57 Pain Relevance 0
As outlined, most of the published data reflect response in hcc metastases, and only a small proportion of our study population fell into this category.
Regulation (response) of hcc associated with metastasis
3) Confidence 0.26 Published 2008 Journal Current Oncology Section Body Doc Link PMC2582509 Disease Relevance 1.03 Pain Relevance 0.22
This study demonstrates that targeting of Mcl-1 by siRNA sensitizes HCC cell lines to chemotherapy and molecularly targeted therapy.
Regulation (sensitizes) of HCC associated with carcinoma
4) Confidence 0.22 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1601962 Disease Relevance 0.72 Pain Relevance 0
The number of factors influencing HCC and its disease course make it extremely difficult to accurately assess patient prognosis and make optimum treatment recommendations.
Regulation (influencing) of HCC associated with hepatocellular cancer and disease
5) Confidence 0.21 Published 2010 Journal International Journal of Clinical Practice Section Body Doc Link PMC2905618 Disease Relevance 0.78 Pain Relevance 0
The aim of the present study was to assess the effectiveness of TACE for HCC in a North American population.
Regulation (effectiveness) of HCC associated with hepatocellular cancer
6) Confidence 0.14 Published 2006 Journal Clin Oncol (R Coll Radiol) Section Abstract Doc Link 17100154 Disease Relevance 0.59 Pain Relevance 0.09
HCC is highly resistant to currently available chemotherapeutic drugs.
Regulation (resistant) of HCC associated with carcinoma
7) Confidence 0.13 Published 2006 Journal BMC Cancer Section Abstract Doc Link PMC1601962 Disease Relevance 1.28 Pain Relevance 0
The effectiveness of interventions fo HCC is influenced by geographical factors related to diverse patient characteristics and protocols.
Regulation (influenced) of HCC associated with hepatocellular cancer
8) Confidence 0.08 Published 2006 Journal Clin Oncol (R Coll Radiol) Section Abstract Doc Link 17100154 Disease Relevance 0.52 Pain Relevance 0.09
Therefore, the inhibition of angiogenesis represents a potential and promising therapeutic target in HCC.
Regulation (target) of HCC associated with hepatocellular cancer
9) Confidence 0.07 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721397 Disease Relevance 0.77 Pain Relevance 0
At present, there is no effective systemic chemotherapy for HCC.
Neg (no) Regulation (effective) of HCC associated with hepatocellular cancer
10) Confidence 0.07 Published 2010 Journal J Transl Med Section Body Doc Link PMC2991329 Disease Relevance 1.71 Pain Relevance 0.09
and its modulation in HCC.

2.

Regulation (modulation) of HCC associated with hepatocellular cancer
11) Confidence 0.04 Published 2008 Journal PPAR Research Section Body Doc Link PMC2396389 Disease Relevance 1.24 Pain Relevance 0.18
These factors represent potential therapeutic targets in HCC treatment (Table 2).
Regulation (targets) of HCC associated with hepatocellular cancer
12) Confidence 0.04 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721397 Disease Relevance 0.68 Pain Relevance 0.07
In addition, the selection of treatment modality for HCC is also highly dependent on the number and size of tumor nodule.
Regulation (dependent) of HCC in nodule associated with cancer and hepatocellular cancer
13) Confidence 0.03 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC3022616 Disease Relevance 1.69 Pain Relevance 0
On the basis of the above phase II studies, a double-blind, placebo-controlled phase III trial of sorafenib in advanced HCC was conducted (Sorafenib HCC Assessment Randomized Protocol Trial: SHARP trial).13 Six hundred and twenty patients with advanced HCC were randomized to receive either sorafenib 400 mg twice daily or placebo.
Regulation (controlled) of HCC associated with hepatocellular cancer
14) Confidence 0.03 Published 2009 Journal OncoTargets and therapy Section Body Doc Link PMC2886319 Disease Relevance 0.70 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox